DVAX logo
DVAX
Dynavax Technologies

Advanced Vaccine Adjuvants Will Capture Expanding Global Demand

AN
AnalystHighTarget
AnalystHighTarget
Not Invested
Consensus Narrative from 4 Analysts
Published
08 May 25
Updated
23 Jul 25
AnalystHighTarget's Fair Value
US$31.00
64.1% undervalued intrinsic discount
23 Jul
US$11.14
Loading
1Y
10.6%
7D
-1.3%

Author's Valuation

US$31.0

64.1% undervalued intrinsic discount

AnalystHighTarget Fair Value